Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Insmed Incorporated

Biotech Cost Dynamics: Neurocrine vs. Insmed

__timestamp	Insmed Incorporated	Neurocrine Biosciences, Inc.
Wednesday, January 1, 2014	33534999	14400000
Thursday, January 1, 2015	1982000	33800000
Friday, January 1, 2016	2438000	35900000
Sunday, January 1, 2017	2901000	1254000
Monday, January 1, 2018	2423000	4889000
Tuesday, January 1, 2019	24212000	7400000
Wednesday, January 1, 2020	39872000	10100000
Friday, January 1, 2021	44152000	14300000
Saturday, January 1, 2022	55126000	23200000
Sunday, January 1, 2023	65573000	39700000
Monday, January 1, 2024		34000000

Infusing magic into the data realm

Cost of Revenue: A Tale of Two Biotechs

In the competitive world of biotechnology, understanding cost structures is crucial. This analysis compares the cost of revenue for Neurocrine Biosciences, Inc. and Insmed Incorporated from 2014 to 2023. Over this period, Insmed's cost of revenue surged by approximately 95%, peaking in 2023. In contrast, Neurocrine Biosciences saw a more modest increase of around 176% over the same period.

Key Insights

2014-2015: Insmed's costs plummeted by 94%, while Neurocrine's costs more than doubled.
2019-2020: Insmed's costs nearly doubled, reflecting strategic investments or increased production.
2023: Both companies reached their highest costs, with Insmed leading by a 65% margin over Neurocrine.

This data highlights the dynamic nature of cost management in biotech, where strategic decisions can significantly impact financial outcomes.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Analyzing Cost of Revenue: Merck & Co., Inc. and Neurocrine Biosciences, Inc.

AstraZeneca PLC vs Insmed Incorporated: Efficiency in Cost of Revenue Explored

Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.

Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc.

Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Insmed Incorporated

Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Catalent, Inc.

Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs BioMarin Pharmaceutical Inc.

Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Exelixis, Inc.

Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated

Viatris Inc. vs Insmed Incorporated: Efficiency in Cost of Revenue Explored

Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Perrigo Company plc

Analyzing Cost of Revenue: Insmed Incorporated and Galapagos NV